Special Drug Use-results Surveillance of Scemblix Tablets

Plain-language summary

This is a surveillance study monitoring the real-world outcomes of treatment in patients receiving Asciminib (Scemblix) in Japan. It included patients treated with Asciminib. The study had no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Novartis Pharmaceuticals

Intervention

Asciminib

Start date

7/4/2022

Estimated completion

2/29/2024

Countries

Japan

Related genes

Locations

• Anjo, Japan
• Ichinomiya, Japan
• Kasugai, Japan
• Komaki, Japan
• Kōnan, Japan
• Nagakute, Japan
• Nagoya, Japan
• Nagoya, Japan
• Nagoya, Japan
• Nagoya, Japan
• Nagoya, Japan
• Seto, Japan
• Toyoake, Japan
• Toyohashi, Japan
• Toyohashi, Japan
• Tōkai, Japan
• Yatomi, Japan
• Ōdate, Japan
• Funabashi, Japan
• Ichihara, Japan
• Ichikawa, Japan
• Kashiwa, Japan
• Kashiwa, Japan
• Kisarazu, Japan
• Matsudo, Japan
• Narita, Japan
• Matsuyama, Japan
• Matsuyama, Japan
• Matsuyama, Japan
• Tōon, Japan
• Yoshida-gun, Japan
• Fukuoka, Japan
• Kitakyushu, Japan
• Kitakyushu, Japan
• Kitakyushu, Japan
• Kurume, Japan
• Yanagawa, Japan
• Aizu-Wakamatsu, Japan
• Fukushima, Japan
• Iwaki, Japan

+238

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* patients treated with asciminib in Japan.

Exclusion Criteria:

NA